drugset / Trial / NCT00766116
Combination 5-azacitidine and Gemtuzumab Ozogamicin Therapy for Treatment of Relapsed Acute Myeloid Leukemia (AML)
Phase 1/2
Completed
50 enrolled
University of California, San Diego
Celgene Corporation · collabPfizer · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
This study will test an experimental combination of the drugs Mylotarg and 5-azacitidine in the hopes of finding a treatment that may be effective against Acute Myeloid Leukemia that has come back after treatment.
Timeline
- Start
- 2005-07
- Primary completion
- 2014-09-26
- Completion
- 2014-09-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azacitidine | Other / unclassified | 75 mg/m2 | — |
| Subject | Gemtuzumab Ozogamicin | Monoclonal antibody | 3 mg/m2 | — |
| Subject | Gemtuzumab Ozogamicin | Monoclonal antibody | 6 mg/m2 | — |